Frequently asked questions about melanotan: answered from the published literature

melanotan refers to two synthetic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH) — Melanotan I (afamelanotide) and Melanotan II — developed at the University of Arizona to study melanogenesis and photoprotection. Both bind melanocortin receptors to trigger eumelanin synthesis and other biological effects depending on which receptor subtype is activated.^[1][2]

MT-I (afamelanotide) is a linear 13-amino-acid analog with high MC1R selectivity; MT-II is a cyclic 7-amino-acid analog with broader MC1R/MC4R/MC3R activity, conferring additional effects on sexual function and appetite not seen with MT-I. MT-I is EU/FDA-approved for erythropoietic protoporphyria; MT-II has no approved indication.^[2]

Both analogs are fully synthetic peptides — not derived from biological sources. They were designed computationally at the University of Arizona as truncated, cyclized versions of the endogenous alpha-MSH tridecapeptide and are manufactured via solid-phase peptide synthesis from standard amino acid precursors.^[1]

Published research has investigated MT-II across four domains: pigmentation and melanogenesis (photoprotection model, Phase I data^[3]), erectile dysfunction (MC4R-mediated erection studies in psychogenic and organic ED^[5][6][7]), appetite and metabolism (MC4R anorexigenic effects in rodent ICV models^[8][9][10]), and peripheral nerve regeneration^[21].

Both analogs bind melanocortin receptors on melanocytes, triggering eumelanin production via the cAMP/PKA/CREB/MITF/tyrosinase cascade.^[4] MT-II's additional MC4R binding accounts for its effects on appetite (paraventricular nucleus, nucleus accumbens) and penile erection (NO-mediated cavernosal signaling) observed in rodent and early human studies.^[5][8]

Phase I data (Dorr et al. 1996) showed measurable pigmentation increases without UV in 2 of 3 subjects.^[3] MT-II activates MC1R directly, bypassing the UV-induced keratinocyte pathway. Subsequent observations suggest minimal UV can accelerate the response, but the peptide alone stimulates baseline eumelanin production without UV.

Hair darkening has been reported in case reports and anecdotal accounts. MC1R is expressed in hair follicle melanocytes, and its activation preferentially increases eumelanin — the mechanistic basis is plausible. Controlled peer-reviewed clinical study data on MT-II-induced hair color change in humans has not been identified in the published literature.

Rodent central infusion studies demonstrated anorexic effects and adiposity reduction via MC4R. Chronic central MTII over 40 days reduced intra-abdominal fat 35–55% in aged rats, with a 3-fold increase in brown adipose tissue thermogenic capacity.^[9] Tolerance to the anorexic effect developed within 5 days in a Zucker rat model, but adiposity reduction was sustained.^[8] No controlled human data on weight or fat-mass reduction from MT-II exists.

Two published case reports document renal adverse events. In one, 27 mg cumulative MT-II over 6 months produced renal infarction affecting approximately 50% of the kidney in a 45-year-old male.^[11] In another, a single 6 mg injection produced rhabdomyolysis (CPK 17,773 IU/L) and acute kidney injury requiring 3-day ICU admission in a 39-year-old man.^[12] Both cases involved doses substantially above Phase I study ranges.

Darkening and new appearance of melanocytic nevi has been documented in published case reports^[13][14] and regulatory safety notices (HPRA, TGA). A 25-year-old developed dysplastic nevi with severe dysplasia on histopathology; a 16-year-old with FAMMM syndrome developed multiple dark nevi that partially reversed after cessation.^[14]

MT-I (afamelanotide/Scenesse) has an established safety record in regulated clinical trials for EPP — 1,023 implants over 8 years with only minor adverse events.^[16] MT-II lacks the same regulatory review. Case reports document nausea,^[3] priapism,^[5] mole changes,^[13][14] renal infarction,^[11] rhabdomyolysis with AKI,^[12] and mucosal malignant melanoma associated with nasal spray use.^[25]

Nausea, facial flushing, and fatigue were the most commonly reported adverse events in Phase I trials and observational case series. Effects were generally dose-dependent and transient in controlled studies.^[3][5][6] The mechanistic basis is central MC4R activation driving oxytocin neuronal firing in hypothalamic nuclei.^[26] The 2021 qualitative forum study of 205 users confirmed nausea and flushing as predominant adverse themes.^[23]

No controlled trial data on testosterone suppression exists for MT-II. A rat co-infusion study found that MT-II did not affect NPY-driven suppression of the gonadotropic axis (LH) or somatotropic axis (GH).^[22] MT-II's pro-erectile signaling operates via central MC4R, not gonadal androgen pathways. Testosterone was not a measured endpoint in any published MT-II human trial.

MT-I (afamelanotide/Scenesse) is EU/FDA-approved for EPP with an established safety record. MT-II has no approved indication; regulatory bodies (FDA, TGA, HPRA, MHRA) classify it as an unapproved substance. Human safety data is limited to small Phase I trials (3–20 subjects). Case reports of serious adverse events from self-administered uncontrolled use are documented in the published literature.^{[11][12][13][25]}

In the Dorr 1996 Phase I trial, pigmentation increases were still measurable 4–6 weeks after the last dose; duration was variable and correlated with baseline Fitzpatrick skin type.^[3] Melanin synthesis continues after rapid peptide clearance, producing the observed persistence.

Research does not support permanent pigmentation. The 2012 Sivyer case report noted skin color paling three months after cessation.^[14] The 2026 Bonchev oral mucosa case showed partial reversal by 28 days post-cessation.^[24] Ongoing UV exposure or re-dosing appears required to maintain elevated pigment levels.

In Phase I trials, objective colorimetric pigmentation increases were measurable at 2–4 weeks of daily subcutaneous dosing.^[3] Subjective tanning was reported by participants within the first week, though objective colorimetry showed slower change. ED effects in the Wessells trials were observed acutely within hours of a single injection.^[5]

Laboratory protocols typically reconstitute lyophilized MT-II with bacteriostatic water at 1–2 mg/mL concentrations. Reconstituted solutions are stored at 4°C and used within published study timeframes per institutional protocols. The cyclic structure provides greater enzymatic resistance than linear alpha-MSH, but standard cold-chain peptide handling applies.

PT-141 (bremelanotide) is a direct chemical descendant of MT-II — a modified form optimized for MC4R activity with reduced MC1R pigmentation effect. PT-141 advanced through FDA trials for hypoactive sexual desire and received approval (2019) for women. The distinction: bremelanotide is FDA-approved while MT-II is approved nowhere.^[19]

MT-II itself has no FDA-approved indication. The approval of its derivative does not change MT-II's regulatory status.

No controlled human data supports a testosterone-raising effect. MT-II's MC4R agonism drives pro-erectile signaling centrally via NO release in cavernosal tissue — not through gonadal androgen pathways. A rodent study confirmed MC4R activation does not modulate the gonadotropic axis.^[22] Testosterone was not a primary endpoint in any published MT-II human trial.

Phase I clinical trials studied MT-II for pigmentation and erectile dysfunction. At 0.025 mg/kg subcutaneous, 8 of 10 men with psychogenic ED had clinically observable erections (Wessells 1998);^[5] 17 of 20 men with organic ED had erections in the larger crossover (Wessells 2000).^[6] Tanning was also observed. Nausea was the predominant adverse event across trials.

MT-I (afamelanotide/Scenesse) is the only approved analog; Phase 3 controlled trials in EPP patients demonstrated significantly reduced phototoxic pain episodes (median 69.4 hours pain-free vs. 40.8 hours placebo in the US study^[15]). This clinical endpoint earned EU (2014) and FDA (2019) regulatory approval. MT-II has not been studied in EPP.

The photoprotection hypothesis was the original University of Arizona rationale. MT-I's EPP trials confirmed meaningful photosensitivity protection in a rare disorder.^[15] Broader photoprotection for general skin cancer prevention remains uninvestigated in Phase III trials for any melanotan family member. The evidence gap between EPP (a severe photosensitivity disorder) and general population photoprotection is substantial.